We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BUTLER TILL MEDIA

Download Mobile App




Events

24 Sep 2019 - 26 Sep 2019
25 Sep 2019 - 27 Sep 2019

New Device Improves Advanced Heart Failure Symptoms

By HospiMedica International staff writers
Posted on 27 Aug 2019
Print article
Image: The Barostim Neo System IPG (Photo courtesy of CVRx).
Image: The Barostim Neo System IPG (Photo courtesy of CVRx).
A novel implant improves symptoms in patients with advanced heart failure (HF) who are not suited for other HF devices.

The CVRx (Maple Grove, MN, USA) Barostim Neo System is a subcutaneous, implantable device designed to electrically activate baroreceptors in the carotid sinus in order to alleviate HF and high blood pressure. The system consists of an implantable pulse generator inserted under the skin, below the collar bone; a two mm electrode attached to the carotid artery and connected to an implantable pulse generator (IPG), which triggers the baroreceptors via electrical stimulation; and a wireless programmer that enables the clinician to customize therapy by adjusting hemodynamic parameters.

The system is indicated for patients who have a regular heart rhythm, are not candidates for a cardiac resynchronization therapy (CRT) device, and have a left ventricular ejection fraction (LVEF) of less than or equal to 35% (below the normal ejection fraction of 55-75%). The device is contraindicated in patients with an anatomy that would impair implantation of the device, certain nervous system disorders, an uncontrolled and symptomatic slow heart rate, atherosclerosis or ulcerative plaques near the implant location, and in patients with a known allergy to silicone or titanium.

“Patients with advanced HF have limitations of physical activity, experiencing fatigue, palpitation, or shortness of breath with activity and may not benefit from standard treatments, including currently marketed drugs and devices,” said Bram Zuckerman, MD, of the U.S. Food and Drug Administration (FDA; Silver Spring, MD, USA) Center for Devices and Radiological Health (CDRH). “This approval provides patients with a new treatment option for the symptoms associated with advanced heart failure.”

Baroreceptors are stretch-sensitive fibers located in the aortic arch and the carotid artery sinus. Their activation triggers an afferent nerve action potential negative-feedback signal to the medulla that helps to maintain normal arterial pressure. When working normally, they buffer fluctuations in blood pressure by causing reflex-mediated reciprocal changes in both heart rate and sympathetic nerve activity, thereby keeping the level of arterial pressure at a predetermined operating level. However, in patients with chronic hypertension, the elevations in pressure threshold can result in decreased baroreceptor activity.

Related Links:
CVRx


Print article

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.